Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation

Expanded Access Use of Adagrasib (MRTX849) for the Treatment of Patients With Advanced Solid Tumors With a KRAS G12C Mutation

The objective of this EAP is to provide expanded access of adagrasib (MRTX849) to patients with previously treated advanced solid tumors harboring a KRAS G12C mutation.

Inclusion Criteria:

• Histologically or cytologically confirmed diagnosis of an advanced/metastatic solid tumor
• Confirmed presence of a KRASG12C mutation
• Ineligible for an ongoing clinical trial of MRTX849
• No available or not eligible for standard of care treatment
• Adequate organ function
• CNS Metastases (within set parameters) are allowed
• ECOG performance status of ≤ 2

Exclusion Criteria:

• History of intestinal disease, inflammatory bowel disease, major gastric surgery, or other gastrointestinal conditions likely to alter absorption of MRTX849 treatment or result in inability to swallow
• Prior therapy targeting a KRAS G12C mutation
• Other active cancer